Pharmacology/Pharmaceutical Industry | Page 29 of 165 | Links Medicus Content Curation & Alerts in Medicine

M-A: Impact of pharmacist-led antimicrobial stewardship on appropriate antibiotic prescribing in the emergency department.

17 Feb, 2022 | 08:23h | UTC

Impact of Pharmacist-Led Antimicrobial Stewardship on Appropriate Antibiotic Prescribing in the Emergency Department: A Systematic Review and Meta-Analysis – Annals of Emergency Medicine (link to abstract – $ for full-text)

Commentary on Twitter

Hot off the Press: Impact of Pharmacist-Led Antimicrobial
Stewardship on Appropriate Antibiotic Prescribing
in the Emergency Department: A Systematic
Review and Meta-Analysis https://t.co/NsZIubli8z pic.twitter.com/V2Sf6tLoKI

— AnnalsofEM (@AnnalsofEM) January 24, 2022

Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review.

16 Feb, 2022 | 10:13h | UTC

Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review – The Lancet Global Health

Commentary on Twitter

A review of the 23 studies of Covid vaccination for immunocompromised people indicates the level of responders varies with conditions. Even additional doses may not provide sufficient protection for some, requiring additional measureshttps://t.co/BjaKrJUAbO @LancetGH pic.twitter.com/EYVWAX23Ig

— Eric Topol (@EricTopol) February 15, 2022

Development of a metric to detect and decrease low-value prescribing in older adults.

16 Feb, 2022 | 09:58h | UTC

Development of a Metric to Detect and Decrease Low-Value Prescribing in Older Adults – JAMA Network Open

Invited Commentary: Considering Value in Prescribing and Deprescribing for Older Adults – JAMA

Commentary on Twitter

In this qualitative study, a scientifically valid and clinically useful low-value prescribing metric was built. EVOLV-Rx may enhance the detection of low-value prescribing practices, reduce polypharmacy, and enable older adults to receive high-value care. https://t.co/GtrsUboT9o

— JAMA Network Open (@JAMANetworkOpen) February 15, 2022

COVID: China is developing its own mRNA vaccine – and it’s showing early promise.

16 Feb, 2022 | 09:56h | UTC

COVID: China is developing its own mRNA vaccine – and it’s showing early promise – The Conversation

WHO Questions and Answers: COVID-19 vaccines and pregnancy.

16 Feb, 2022 | 09:53h | UTC

Questions and Answers: COVID-19 vaccines and pregnancy – World Health Organization

COVID vaccines safely protect pregnant people: the data are in.

COVID-19 vaccination in pregnancy—number needed to vaccinate to avoid harm.

A case-controlled study showed Covid-19 vaccination during early pregnancy was not associated with increased risk of first-trimester miscarriage.

Editorial: Covid-19 treatments and vaccines must be evaluated in pregnancy.

AstraZeneca vaccination not linked to reduced fertility rates and adverse birth outcomes.

Cohort study: Vaccinated pregnant patients had 90% lower risk of severe or critical Covid-19 compared with unvaccinated pregnant patients.

Two observational studies suggest spontaneous abortion is not increased following COVID-19 mRNA vaccination during pregnancy.

Study shows high effectiveness of the Pfizer mRNA COVID-19 vaccine in pregnancy.

5 Crucial Things to Know About COVID-19 Vaccines and Pregnancy.

CDC Guidance: Pregnant people should be vaccinated against COVID-19.

ACOG and SMFM Recommend COVID-19 Vaccination for Pregnant Individuals – “ACOG encourages its members to enthusiastically recommend vaccination to their patients.”

Cohort study: Pfizer/BioNTech COVID vaccine associated with 78% lower risk of Covid-19 in pregnancy.

Commentary on Twitter

? Summary of WHO recommendations on #COVID19 vaccination in pregnancy https://t.co/XPVggBbSmj

If you’re pregnant, vaccination is one of the most important ways to protect yourself and your baby from severe illness from COVID-19. pic.twitter.com/dfSBVJLBG7

— World Health Organization (WHO) (@WHO) February 15, 2022

Covid-19: Vaccination during pregnancy is safe, finds large US study.

16 Feb, 2022 | 09:51h | UTC

Covid-19: Vaccination during pregnancy is safe, finds large US study – The BMJ

Original Study: Receipt of COVID-19 Vaccine During Pregnancy and Preterm or Small-for-Gestational-Age at Birth — Eight Integrated Health Care Organizations, United States, December 15, 2020–July 22, 2021 – CDC Morbidity and Mortality Weekly Report

COVID vaccines safely protect pregnant people: the data are in.

COVID-19 vaccination in pregnancy—number needed to vaccinate to avoid harm.

A case-controlled study showed Covid-19 vaccination during early pregnancy was not associated with increased risk of first-trimester miscarriage.

Editorial: Covid-19 treatments and vaccines must be evaluated in pregnancy.

AstraZeneca vaccination not linked to reduced fertility rates and adverse birth outcomes.

Cohort study: Vaccinated pregnant patients had 90% lower risk of severe or critical Covid-19 compared with unvaccinated pregnant patients.

Two observational studies suggest spontaneous abortion is not increased following COVID-19 mRNA vaccination during pregnancy.

Study shows high effectiveness of the Pfizer mRNA COVID-19 vaccine in pregnancy.

5 Crucial Things to Know About COVID-19 Vaccines and Pregnancy.

CDC Guidance: Pregnant people should be vaccinated against COVID-19.

ACOG and SMFM Recommend COVID-19 Vaccination for Pregnant Individuals – “ACOG encourages its members to enthusiastically recommend vaccination to their patients.”

Cohort study: Pfizer/BioNTech COVID vaccine associated with 78% lower risk of Covid-19 in pregnancy.

Meta-analysis of randomized clinical trials: vaccines to prevent COVID-19.

15 Feb, 2022 | 10:04h | UTC

Vaccines to prevent COVID-19: A living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials – PLOS One

Systematic Review: Efficacy of antiviral therapies for COVID-19.

15 Feb, 2022 | 10:02h | UTC

Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials – BMC Infectious Diseases

Covid-19: Fourth vaccine doses—who needs them and why?

15 Feb, 2022 | 09:59h | UTC

Covid-19: Fourth vaccine doses—who needs them and why? – The BMJ

EAACI Position Paper: Hypersensitivity reactions to chemotherapy.

15 Feb, 2022 | 09:54h | UTC

Hypersensitivity reactions to chemotherapy: an EAACI Position Paper – Allergy

Cluster Randomized Clinical Trial: An electronic decision support system for deprescribing in hospitalized older adults was safe and led to improvements in deprescribing but did not reduce adverse drug events.

15 Feb, 2022 | 09:43h | UTC

The MedSafer Study—Electronic Decision Support for Deprescribing in Hospitalized Older Adults: A Cluster Randomized Clinical Trial – JAMA Internal Medicine

Commentary on Twitter

Randomized control trial found that @MedSaferTool increases #deprescribing by 22% at hospital discharge but little impact on short term adverse drug events. https://t.co/XqiSwFSPEz @DrEmilyMcD @DrToddLee @DeprescribeUS

— JAMA Internal Medicine (@JAMAInternalMed) January 18, 2022

Pfizer and FDA pull back from plan to expedite review of Covid-19 vaccine in children under 5.

13 Feb, 2022 | 22:51h | UTC

Pfizer and FDA pull back from plan to expedite review of Covid-19 vaccine in young children – STAT

Novavax says protein vaccine works for kids as young as 12.

13 Feb, 2022 | 22:54h | UTC

Novavax says protein vaccine works for kids as young as 12 – Associated Press

Press Release: Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial

Randomized trial with nearly 30.000 individuals showed Novavax vaccine was safe and had an overall efficacy of 90.4% against symptomatic infections.

RCT: Novavax vaccine conferred 89.7% protection against symptomatic SARS-CoV-2 infection and 100% protection against hospitalizations or deaths.

Opinion | The mRNA vaccines are extraordinary, but Novavax is even better.

(Press release – not published yet) Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease.

RCT: Novavax vaccine is 49.4% effective against B.1.351 SARS-CoV-2 variant.

[Press release – not published yet] Novavax reports 96% efficacy against original strain of COVID-19, 86% efficacy against B.1.1.7 variant, and 55% efficacy against B1.351 variant

New COVID-19 vaccines: here’s how the promising Novavax and Johnson & Johnson jabs work

Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant

Conflicting reports raise questions about whether any monoclonals work against Omicron’s sister variant.

13 Feb, 2022 | 22:49h | UTC

Conflicting reports raise questions about whether any monoclonals work against Omicron’s sister variant – STAT

FDA halts use of antibody drugs that don’t work vs. Omicron.

Lab study shows new antiviral pills maintain efficacy against Omicron, but antibody drugs are substantially less effective.

Special Issue: Evidence-based strategies for better antibiotic prescribing in primary care.

13 Feb, 2022 | 22:40h | UTC

Editorial: Antibiotic stewardship – Australian Journal of General Practice

Antibiotic stewardship: A review of successful, evidence-based primary care strategies – Australian Journal of General Practice

Evidence-based strategies for better antibiotic prescribing – Australian Journal of General Practice

How can general practitioners reduce antibiotic prescribing in collaboration with their patients? – Australian Journal of General Practice

Review: Global accessibility of therapeutics for diabetes mellitus.

13 Feb, 2022 | 21:51h | UTC

Global accessibility of therapeutics for diabetes mellitus – Nature Reviews Endocrinology (if the link is paywalled, try this one)

New WHO report maps barriers to insulin availability and suggests actions to promote universal access – “100 years after its discovery, insulin still out of reach for many living with diabetes”.

Editorial | Insulin for all: a hope yet to be realized.

One hundred years of insulin therapy.

The state of diabetes treatment coverage in 55 low-income and middle-income countries – fewer than one in ten people with diabetes in LMICs receive comprehensive care such as low-cost medicines to reduce blood sugar, blood pressure and cholesterol levels, in addition to counseling on diet, exercise and weight.

IDSA guidance and ESCMID guidelines: complementary approaches toward a care standard for MDR Gram-negative infections.

11 Feb, 2022 | 08:51h | UTC

IDSA guidance and ESCMID guidelines: complementary approaches toward a care standard for MDR Gram-negative infections – Clinical Microbiology and Infection

Original Guidelines:

European guidelines for the treatment of infections caused by Multidrug-resistant Gram-negative bacilli.

IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.

AHA Scientific Statement | How does cannabis use affect brain health? Caution advised, more research needed.

11 Feb, 2022 | 08:53h | UTC

News Release: How does cannabis use affect brain health? Caution advised, more research needed – American Heart Association

Original Statement: Use of Marijuana: Effect on Brain Health: A Scientific Statement From the American Heart Association – Stroke

Commentary on Twitter

Use of Marijuana: Effect on Brain Health: A Scientific Statement From the American Heart Association #BrainHealth #ISC22 #AHAJournals https://t.co/LoGbVRfzf4 @American_Heart pic.twitter.com/DyNbFzA0Lw

— Stroke AHA/ASA (@StrokeAHA_ASA) February 10, 2022

Discontinuing antidepressants: Pearls and pitfalls.

11 Feb, 2022 | 08:18h | UTC

Discontinuing antidepressants: Pearls and pitfalls – Cleveland Clinic Journal of Medicine

RCT: Subcutaneous Tirzepatide added to titrated Insulin Glargine improves glycemic control in patients with Type 2 Diabetes.

10 Feb, 2022 | 10:00h | UTC

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Tirzepatide for Patients With Type 2 Diabetes – JAMA

Commentary: SURPASS-5 Data: Tirzepatide Plus Insulin Glargine Improve Glycemic Control in T2D – AJMC

RCT: In patients with Type 2 Diabetes, Tirzepatide is associated with reduced weight, improved glycemic control, and lower risk of hypoglycemia compared to insulin glargine.

RCT: Once-weekly tirzepatide vs. once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes.

RCT: Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2.

RCT: Tirzepatide yielded greater glycated hemoglobin and body weight reductions compared to Semaglutide 1 mg.

Culprit medications and risk factors associated with Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A population-based nested case–control study.

10 Feb, 2022 | 08:42h | UTC

Culprit Medications and Risk Factors Associated with Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Population-Based Nested Case–Control Study – American Journal of Clinical Dermatology

Short Review: Biologics for episodic and chronic migraines.

10 Feb, 2022 | 08:40h | UTC

Biologics for episodic and chronic migraines – Canadian Family Physician

European guidelines for the treatment of infections caused by Multidrug-resistant Gram-negative bacilli.

9 Feb, 2022 | 10:18h | UTC

European Society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by Multidrug-resistant Gram-negative bacilli (endorsed by ESICM –European Society of intensive care Medicine) – Clinical Microbiology and Infection

Though rare, Moderna Covid vaccine recipients have higher risk of heart inflammation than Pfizer.

9 Feb, 2022 | 10:06h | UTC

Though rare, Moderna Covid vaccine recipients have higher risk of heart inflammation than Pfizer – CNBC

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

[Preprint] Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy.

9 Feb, 2022 | 10:08h | UTC

Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy: a multi-database, self-controlled case series study -medRxiv

Myocarditis after BNT162b2 vaccination in Israeli adolescents.

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

Commentary on Twitter

The incidence of mRNA vaccine myocarditis or pericarditis in Italy in ~3 million vaccinees age 12-39. Excess cases per 100,000; orange is 2nd dose, blue 1st dose. https://t.co/xvdV4qSdHw
Pfizer:~1/100,000 age 12-39, all 2nd dose
Moderna,: >5/100,000, age 12-39, and some 1st dose pic.twitter.com/Y1jfGrU53v

— Eric Topol (@EricTopol) February 9, 2022

Stay Updated in Your Specialty